



Food and Drug Administration  
OFFICE OF CRIMINAL INVESTIGATIONS  
MEMORANDUM OF INTERVIEW

**CASE NUMBER:** 2005-MWM-715-0153-J  
**CASE TITLE:** ALBERT POET  
**DOCUMENT NUMBER:** 99931  
**PERSON INTERVIEWED:** Joan H [REDACTED]  
**PLACE OF INTERVIEW:** Camden County, New Jersey  
**DATE OF INTERVIEW:** 08/23/2006  
**TIME OF INTERVIEW:** 8:45 p.m.  
**INTERVIEWED BY:** Marc Hess, Special Agent

**OTHER PERSONS PRESENT:**

Joan H [REDACTED] was telephonically contacted at 609/[REDACTED]. After being advised of the identity of the interviewing agent and the nature of this interview, H [REDACTED] provided the following information:

H [REDACTED] was interviewed by Special Agent (SA) Marc Hess concerning this matter in 2005. She recently received a letter from FDA concerning this matter. She then left a message with SA Hess indicating that she had already been interviewed but that Dr. Albert Poet had recently contacted her.

Approximately three weeks ago a female who advised that she was calling on behalf of Poet called H [REDACTED] at the above telephone number and asked if she would speak with Poet. H [REDACTED] refused. H [REDACTED] advised that she remains upset with Dr. Poet and concerned with her health due to what she believed was faulty Botox-type treatment by him. H [REDACTED] further advised that she has sinus problems and a disorder in a muscle of her left side of the face which she believes is associated with this poor treatment by Poet. H [REDACTED] continues to seek medical treatment for these conditions.

The above telephone number is H [REDACTED] residential number with Verizon as provider. H [REDACTED] believed that the call occurred before noon. H [REDACTED] also believed that she had the date of the call indicated on a calendar but it was not readily available during this interview.

H [REDACTED] conferred with her husband after refusing to speak with Poet and terminating the call. H [REDACTED] husband suggested that Poet might be able to provide medical information to assist in treating H [REDACTED] condition so she should agree to speak with Poet. H [REDACTED] then dialed (\*) 69, reached the same female and requested to speak with Poet. H [REDACTED] could not recall whether the female indicated that this was Poet's office but Poet did present himself to speak on the telephone.

Poet indicated that he wished to advise H [REDACTED] that in July 2004 he had administered a "not yet approved" by the FDA form of Botox to H [REDACTED]. At the time Poet had the impression that the drug was about to be approved. Poet further indicated that the drug was now in the pipeline to be approved. Poet further advised that he would like H [REDACTED] permission to have representatives of the manufacturers of the drug interview H [REDACTED] concerning her experience. H [REDACTED] did not recall the precise language used by Poet but believes that the above accurately describes what he communicated to her. H [REDACTED] was not sure whether Poet used the word "Botox" or "Botulinum Toxin".

H [redacted] replied to Poet that he had "almost killed" her with the previous Botox treatment. Poet replied that her medical condition could not have been related to his treatment of her and asked whether she had been tested.

H [redacted] then informed Poet that she had been interviewed by the FDA regarding this matter and she hoped that he had "ill luck" in his life.

**NAME-TITLE** \_\_\_\_\_ **NAME-TITLE** \_\_\_\_\_  
Marc Hess, Special Agent

**DATE** 08/30/2006 **DATE**

**APPROVED:** \_\_\_\_\_  
Kim A. Rice, Special Agent in Charge

**DATE:** 09/30/2006

**DISTRIBUTION:** ORIG: MWM  
CC: AD-IOD  
CC: MIF - SA KORB  
CC: PHP

**ATTACHMENTS:** n/a